Summary:
Summary Statement of Deficiencies D0000 An announced CLIA recertification survey was conducted at VPI Student Health Center, Schiffert Health Center on March 5, 2026 by the Virginia Department of Health's Office of Licensure and Certification. The laboratory was surveyed under 42 CFR part 493 CLIA Requirements. Specific deficiencies cited are as follows: D5215 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(b)(2) The laboratory must verify the accuracy of any analyte, specialty or subspecialty assigned a proficiency testing score that does not reflect laboratory test performance (that is, when the proficiency testing program does not obtain the agreement required for scoring as specified in subpart I of this part, or the laboratory receives a zero score for nonparticipation, or late return or results). This STANDARD is not met as evidenced by: Based on a review of proficiency testing (PT) records, procedures, lack of documentation, and interview, the laboratory failed to evaluate four chemistry, one microscopy, and nine microbiology non-graded analyte challenges resulted on six of six events reviewed for calendar years 2024 and 2025. Findings include: 1. Review of the laboratory's American Proficiency Institute (API) PT results (2024 Events 1-3, 2025 Events 1-3), a total of 6 events, revealed that API released non-graded analyte responses for: Total Bilirubin (T Bili) due to variance on the following 3 events: API 2024 Event 1 - T Bili challenge CH-02; API 2025 Event 2 - T Bili challenge CH-07; API 2025 Event 3 - T Bili challenges CH-12; Alkaline Phosphatase (ALKP) on the following event: API 2025 Event 2 - ALKP challenge CH-06; --a total of 4 non- graded Core Chemistry challenge samples were reported by API; Vaginal Wet Prep on the following event: API 2024 Event 2 - challenge VA-02; --a total of one non- graded microscopy challenge sample was reported by API; Urine Culture Susceptibility on the following 2 events: API 2024 Event 1 - Susceptibility UR-01 Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- Trimethoprim/Sulfamethoxazole (Trimeth/Sulfa) API 2024 Event 2 - Susceptibility UR-06; Ciprofloxacin (Cipro) --a total of 2 non-graded microbiology urine culture susceptibility challenge samples were reported by API; Urine Culture MIC/Zone Value on the following: API 2024 Event 1 - challenge UR-01 Cipro, Nitrofurantoin, Trimeth/Sulfa; API 2024 Event 2 - challenge UR-06 Cipro; API 2024 Event 3 - challenge UR-11 Ampicllin (Amp), Cefoxitin, Cipro, API 2025 Event 1 - challenges UR-01 Amp, Cefoxitin, Cipro, Nitrofurantoin and UR-02 Amp; API 2025 Event 2 - challenges UR-06 and UR-07 Amp, Cefoxitin, Cipro, Nitrofurantoin; --a total of 7 non-graded microbiology urine culture MIC/Zone value challenge samples were reported by API. 2. Review of the laboratory's PT review documentation revealed no evaluation/verification of accuracy recorded for the non-graded challenge sample results outlined above. The inspector requested to review an evaluation for the non- graded challenges. The documentation was not available. 3. Review of the laboratory's procedures revealed a policy (title: Proficiency Testing Policy) that stated, "Nongraded and educational challenges are to be compared to the peer group and clearly documented on the evaluation form. PT results which are not graded due to lack of consensus, submitting results too late, failure to submit, etc. are to be reviewed by the manager with appropriate follow-up and documentation of